Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 13.6b

Immunosuppression Use for Induction by Discharge Regimen, 2004 to 2008

Recipients with Heart-Lung Transplants

  Discharge Regimen (w/ or w/o Steroids Use) All
CyA Tac CyA+ MMF Tac+ MMF CyA+ Aza Tac+ Aza Tac+ Siro Other
Functioning Graft with Immunosuppression Info at Discharge 2 11 13 75 19 11 1 4 136
% of All Regimens 1.5% 8.1% 9.6% 55.1% 14.0% 8.1% 0.7% 2.9% 100.0%
Induction Drug 0.0% 9.1% 15.4% 14.7% 31.6% 0.0% 0.0% 50.0% 16.2%
Atgam/NRATG/NRATS
OKT3 0.0% 9.1% 7.7% 1.3% 5.3% 0.0% 0.0% 0.0% 2.9%
Thymoglobulin 0.0% 0.0% 0.0% 9.3% 0.0% 9.1% 100.0% 0.0% 6.6%
Zenapax 0.0% 18.2% 23.1% 17.3% 26.3% 18.2% 0.0% 75.0% 20.6%
Simulect 0.0% 9.1% 38.5% 10.7% 15.8% 36.4% 0.0% 50.0% 16.9%
Campath 0.0% 18.2% 0.0% 20.0% 0.0% 0.0% 0.0% 75.0% 14.7%
No Induction Drugs Recorded 100.0% 54.5% 23.1% 29.3% 26.3% 36.4% 0.0% 0.0% 30.9%


Source: OPTN/SRTR Data as of May 4, 2009.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.



PDF FormatRequires Adobe Acrobat Reader